

Community Care Centers of Excellence Concept Overview

March 10, 2025 CIRM Access and Affordability Working Group





Table of Contents

- 1. Background
- 2. CCCE Concept Plan
 - 1. Objective
 - 2. Structure
 - 3. Eligibility
 - 4. Timeline
- 3. Request for Motion





Program Mandate

Community Care Centers of Excellence are infrastructure described in Proposition 14.



Establish the Community Care Centers of Excellence Program to:

- Expand the capacity of the Alpha Clinics
- Promote access to human clinical trials and the accessibility of treatments and cures arising from institute-funded research
- Establish geographically diverse centers of excellence to conduct clinical trials and to seek to make the resulting treatments and cures broadly available to California patients.





Goal 5 | Recommendations

Goal 5 - Ensure that every BLA ready program has a strategy for access and affordability


Strengthen Clinical Infrastructure Connectivity

➤ Build interconnectivity & performance metrics between CIRM Clinical Infrastructure (Alpha Clinics, CCCEs, PSPs) to ensure enhanced **referral**, **enrollment**, & **retention** of California patients in clinical trials





Objective of CIRM's Clinical Infrastructure








CCCE Initial Cycle

	CCCE INFR 8		
Structure	1) a Support Site or (2) a Support and Delivery Site.		
Applications Received	• 9 Total		
	> 4 x Support Only Sites and		
	> 5 x Support and Delivery Sites		
GWG/FWG Outcome	• 1 x Support Only Site - Funding recommendation		
	• 8 x applications - Not recommended for funding		





CCCE Budget considerations



• By **revising** the concept, we aim to provide a sustainable financial framework for both CCCEs and support-only activities





Key Insights from the First CCCE Round

- Sustainability Concerns The initial funding structure would have exhausted nearly the entire CCCE budget in one cycle, leaving little for future awards or program expansion
- ➤ **Geographic Diversity Gaps** While applications came from various areas, they didn't fully align with our goal of expanding access to underserved regions
- Program Alignment with Proposition 14 Applications didn't fully capture the integration of clinical trial delivery and long-term patient support, which are core to the CCCE vision
- Need for comprehensive approach to fully fund delivery and support

These considerations led us to refine the concept plan, ensuring a stronger, more sustainable, and more impactful approach





Transitioning to a Two-Phase Model

Refining: Two-Phase Approach for Sustainability

Category	2025	2026	2027	2028	2029	2030
CCCE	Delivery RFA	First Cycle Sites Active				
Delivery			[elivery RFA	Second Cycl	e Sites Active
AAWG Support	Support RFA			Suppor	t RFA	

Category	Funding Amount	Source
CCCE Delivery	\$78M (2 funding cycles)	Proposition 14 (earmarked for CCCEs)
AAWG Support	\$93M **	Patient Access & Affordability allocations

^{* &}quot;RFA" timeline includes RFA development, application review, and award contracting

^{**} Available funding for patient access & affordability allocations – NOT all for support RFAs



CCCE Phase 1 - Concept

- 1. Objective
- 2. Structure
- 3. Eligibility
- 4. Timeline

Objective

Expand **geographically diverse** centers of excellence across California to enhance patient access to regenerative medicine treatments by:

- (1) Expanding the reach and delivery of clinical trials and approved therapies, and
- (2) Developing a **skilled workforce** to support the **delivery** of regenerative medicine treatments and ensure **broad accessibility**, particularly in **underserved communities**.

Award Structure

	CCCE INFR 8		
Max Duration	5 years		
Applicant	 CA non-profit or for-profit research institutions in good standing Commitment to CGT treatment from any source Organization does not have an INFR4 award Only providing FDA-authorized treatments 		
Core Team	Program Director (30%)		
Max Award	\$9 M (total cost capped)		
Program Budget (FY25/26)	\$36,000,000		

CCCE | Eligibility

	Eligibility Requirements	
Applicant	 California Organization Must not be currently funded under CIRM's Alpha Clinics (INFR 4) Program 	
Expected Outcome	 Must have demonstrated ability to perform human clinical trials Must have or propose to develop capability to deliver regenerative medicine clinical trials and approved products Must propose at least one partnership with a community-based organization or organizations to support clinical research, career development, or engagement 	
Award Start	Must be ready to initiate work on the funded project within 120 days of award approval	
Program Director (PD)	30% effort	


BOLD: Update from initial concept plan



Concept Launch Timeline

Application to award start ~ 10 months

Awards start in March 2026



Engage AAWG to consider funding opportunity for Support-Only activities

Request for Motion

We request a motion that the Access & Affordability Working Group recommend approval of the revised **CCCE Concept** to the full ICOC